Estradiol transdermal system is indicated for the prevention of postmenopausal osteoporosis. The drug will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad.
Estradiol Transdermal System USP, 0.014 mg/day (weekly) had annual sales of $1.9 million in the US.
The group now has 363 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy